The scope of the GAPP Project is to make medicines available for children with chronic pain of neuropathic origin, a condition for which the paediatric therapeutic need is very high and well recognized.
The drug to be developed is gabapentin, which is already being used for the treatment of neuropathic chronic pain in adults.
The proposed research plan has received the full approval from the Paediatric Committee of the European Medicines Agency (PDCO), which comments that: “There is a significant therapeutic need in the management of pain in children, not only in the availability of child appropriate formulations but also in generating efficacy and safety data in pharmacological agents of different classes.”
